Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2015 | Overview of RESONATE-2 clinical trial of ibrutinib in CLL

John Gribben and Stephan Stilgenbauer • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia Ibrutinib
RESONATE-2

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben et al. • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben et al. • 9 Dec 2023
The future of CLL therapy
1:04
The future of CLL therapy
John Gribben et al. • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
John Gribben et al. • 17 Oct 2023

More from Stephan Stilgenbauer

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
John Gribben et al. • 11 Dec 2023
Acquired mutations associated with resistance to BTKi in patients with CLL
2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
John Gribben et al. • 11 Dec 2023
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
John Gribben et al. • 11 Dec 2023
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
John Gribben et al. • 11 Dec 2023

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
John Gribben et al. • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
John Gribben et al. • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
John Gribben et al. • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
John Gribben et al. • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals